Yoshiaki Sagara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yoshiaki Sagara has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Hirofumi Mukai
Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan
2 shared publications - Yasuaki Sagara
Department of Breast Surgical Oncology, Sagara Hospital, Kagoshima, Japan
2 shared publications - Yasuo Ohashi
Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo, Japan
2 shared publications - Akihide Tanimoto
Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima City, Japan
1 shared publication Akihiko Osaki
Department of Breast Oncology , Saitama Medical University International Medical Center , Hidaka, Saitama
1 shared publicationEisuke Fukuma
Breast Center, Kameda Medical Center, Kamogawa, Chiba
1 shared publication
Latest Publications
- Open Access
Circulating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis
A lack of reliable biomarkers for oral squamous cell carcinoma (OSCC) poses a major clinical issue. The sensitivity and specificity of classical serum tumor markers, such as the squamous cell carcinoma antigen (SCC-Ag), are quite poor, especially for early detection. This study aimed to identify specific serum miRNAs potentially serving as OSCC biomarkers. The expression levels of candidate miRNAs in serum samples from 40 OSCC patients and 40 healthy controls were quantitatively analyzed via microarray and reverse transcription PCR (RT-PCR) analyses. To enhance the accuracy of detection, we used Fisher’s linear discriminant analysis to establish a diagnostic model that incorporated a combination of selected miRNAs. Consequently, miR-19a and miR-20a were significantly upregulated in the patient group (p = 0.014 and 0.036, respectively), whereas miR-5100 was downregulated (p = 0.001). We found that a combination of six miRNAs (miR-24, miR-20a, miR-122, miR-150, miR-4419a, and miR-5100) could distinguish between OSCC and the control group with a higher degree of accuracy (Area Under the Curve, AUC: 0.844, sensitivity: 55%, and specificity: 92.5%). Furthermore, compared to serum SCC antigen, the 6-miRNA panel could accurately detect the presence of OSCC. The present specific miRNAs panel may serve as a novel candidate biomarker of oral cancer.
Open AccessCirculating microRNA Panel as a Potential Novel Biomarker for Oral Squamous Cell Carcinoma Diagnosis
A lack of reliable biomarkers for oral squamous cell carcinoma (OSCC) poses a major clinical issue. The sensitivity and specificity of classical serum tumor markers, such as the squamous cell carcinoma antigen (SCC-Ag), are quite poor, especially for early detection. This study aimed to identify specific serum miRNAs potentially serving as OSCC biomarkers. The expression levels of candidate miRNAs in serum samples from 40 OSCC patients and 40 healthy controls were quantitatively analyzed via microarray and reverse transcription PCR (RT-PCR) analyses. To enhance the accuracy of detection, we used Fisher’s linear discriminant analysis to establish a diagnostic model that incorporated a combination of selected miRNAs. Consequently, miR-19a and miR-20a were significantly upregulated in the patient group (p = 0.014 and 0.036, respectively), whereas miR-5100 was downregulated (p = 0.001). We found that a combination of six miRNAs (miR-24, miR-20a, miR-122, miR-150, miR-4419a, and miR-5100) could distinguish between OSCC and the control group with a higher degree of accuracy (Area Under the Curve, AUC: 0.844, sensitivity: 55%, and specificity: 92.5%). Furthermore, compared to serum SCC antigen, the 6-miRNA panel could accurately detect the presence of OSCC. The present specific miRNAs panel may serve as a novel candidate biomarker of oral cancer.
- Open Access
- 17 November 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 773
Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effectiveness was a secondary endpoint of the SELECT BC trial, some of the randomized patients participated in an EQ-5D survey (N = 391) and health economic survey (N = 146). The EQ-5D responses, claims, and prescription data were collected for as long as possible until death. The expected quality-adjusted life years (QALY) obtained from each treatment were calculated using patient-level EQ-5D data, and the expected cost was calculated using patient-level claim data. The analysis was performed from the perspective of public healthcare payers. The estimated EQ-5D least-square means and 95% CI up to 48 months were 0.764 (95% CI, 0.741–0.782) and 0.742 (95% CI, 0.720–0.764) in the S-1 and taxane arms, respectively. The expected QALY was 2.11 for the S-1 arm and 2.04 for the taxane arm, with expected costs of JPY 5.13 million (USD 46,600) and JPY 5.56 million (USD 50,500), respectively. These results show that S-1 is cost-saving. According to probabilistic sensitivity analysis, S-1 was dominant with a probability of 63%. When the willingness to pay (WTP) value was JPY 5 million (USD 45,500) per QALY, the probability of being cost-effective was 92%. Our results show that the introduction of oral S-1 therapy for metastatic breast cancer is highly likely to be cost-effective. UMIN CTR C000000416 . Registered on May 10, 2006.
- 17 November 2017
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 773
Open AccessCost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial
This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effectiveness was a secondary endpoint of the SELECT BC trial, some of the randomized patients participated in an EQ-5D survey (N = 391) and health economic survey (N = 146). The EQ-5D responses, claims, and prescription data were collected for as long as possible until death. The expected quality-adjusted life years (QALY) obtained from each treatment were calculated using patient-level EQ-5D data, and the expected cost was calculated using patient-level claim data. The analysis was performed from the perspective of public healthcare payers. The estimated EQ-5D least-square means and 95% CI up to 48 months were 0.764 (95% CI, 0.741–0.782) and 0.742 (95% CI, 0.720–0.764) in the S-1 and taxane arms, respectively. The expected QALY was 2.11 for the S-1 arm and 2.04 for the taxane arm, with expected costs of JPY 5.13 million (USD 46,600) and JPY 5.56 million (USD 50,500), respectively. These results show that S-1 is cost-saving. According to probabilistic sensitivity analysis, S-1 was dominant with a probability of 63%. When the willingness to pay (WTP) value was JPY 5 million (USD 45,500) per QALY, the probability of being cost-effective was 92%. Our results show that the introduction of oral S-1 therapy for metastatic breast cancer is highly likely to be cost-effective. UMIN CTR C000000416 . Registered on May 10, 2006.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v2
Current Perspective of Chemotherapy in Metastatic Breast Cancer: New Evidence From Select Bc Trial
While living with metastatic breast cancer presents challenges, there are many options available for chemotherapy. The goal for many patients is to stay on treatment as long as it successfully relieves symptoms and slows tumor growth. Taxanes have been a mainstay of chemotherapy for patients with metastatic breast cancer at the cost of side effects, which sometimes are not trivial. TS-1 is an orally available 5-fluorouracil derivative, and multiple clinical trials have demonstrated its clinical efficacy and tolerability. Recently, a phase III open-label randomized controlled trial was conducted in Japan to test the non-inferiority of TS-1 in terms of overall survival (OS) to taxanes at first line in patients with metastatic breast cancer. Previously untreated metastatic breast cancer patients were assigned to either taxanes or TS-1 in the study. The primary endpoint of the study was OS, and secondary endpoints include time to treatment failure (TTF) and health-related QOL. Non-inferiority of TS-1 to taxanes was demonstrated in OS and TTF with statistical significance, and toxicity profile of TS-1 was mild to maintain the QOL of the patients in the study. Chemotherapy for breast cancer should focus on maintaining a patient's QOL while minimizing side effects, and roles of oral fluoropyrimidine and conventional agents such as taxanes and anthracyclines in breast cancer chemotherapy will be discussed at the conference.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25, v2
Current Perspective of Chemotherapy in Metastatic Breast Cancer: New Evidence From Select Bc Trial
While living with metastatic breast cancer presents challenges, there are many options available for chemotherapy. The goal for many patients is to stay on treatment as long as it successfully relieves symptoms and slows tumor growth. Taxanes have been a mainstay of chemotherapy for patients with metastatic breast cancer at the cost of side effects, which sometimes are not trivial. TS-1 is an orally available 5-fluorouracil derivative, and multiple clinical trials have demonstrated its clinical efficacy and tolerability. Recently, a phase III open-label randomized controlled trial was conducted in Japan to test the non-inferiority of TS-1 in terms of overall survival (OS) to taxanes at first line in patients with metastatic breast cancer. Previously untreated metastatic breast cancer patients were assigned to either taxanes or TS-1 in the study. The primary endpoint of the study was OS, and secondary endpoints include time to treatment failure (TTF) and health-related QOL. Non-inferiority of TS-1 to taxanes was demonstrated in OS and TTF with statistical significance, and toxicity profile of TS-1 was mild to maintain the QOL of the patients in the study. Chemotherapy for breast cancer should focus on maintaining a patient's QOL while minimizing side effects, and roles of oral fluoropyrimidine and conventional agents such as taxanes and anthracyclines in breast cancer chemotherapy will be discussed at the conference.
- Open Access
- 14 July 2013
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 43 (9) , 865-873
The Efficacy and Safety of FSK0808, Filgrastim Biosimilar: A Multicenter, Non-randomized Study in Japanese Patients with Breast Cancer
FSK0808 is a filgrastim biosimilar. This study assessed the efficacy and safety of FSK0808 in patients with breast cancer. One hundred and four breast cancer patients undergoing chemotherapy were enrolled in the study. FSK0808 was used to treat the neutropenia experienced by the patients in the course of their chemotherapy. Efficacy was evaluated by the recovery of absolute neutrophil count following FSK0808 administration based on the duration of neutropenia in patients who received pre- or postoperative chemotherapy containing fluorouracil, epirubicin and cyclophosphamide. Adverse events were evaluated in accordance with the Common Terminology Criteria for Adverse Events version 3.0. The incidence of febrile neutropenia and generation of an anti-granulocyte colony-stimulating factor antibody were also evaluated. The average duration of neutropenia in Cycle 2 was 2.2 days with a standard deviation of 1.5 days. The upper limit of the 97.5% one-sided confidence interval was 2.5 days and was confirmed not to exceed 3.0 days, which was defined as the threshold value of absolute neutrophil count recovery. The incidence of febrile neutropenia across all treatment cycles was 34.6%. Observed adverse drug reactions with an incidence of >5% were back pain (60.6%), bone pain (9.6%), alanine aminotransferase increase (8.7%), aspartate aminotransferase increase (5.8%) and arthralgia (5.8%). Production of the anti-granulocyte colony-stimulating factor antibody was not observed in any patient during the study. FSK0808 was safe and well tolerated in breast cancer patients undergoing chemotherapy and effectively stimulated neutrophil recovery.
- 14 July 2013
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 43 (9) , 865-873
Open AccessThe Efficacy and Safety of FSK0808, Filgrastim Biosimilar: A Multicenter, Non-randomized Study in Japanese Patients with Breast Cancer
FSK0808 is a filgrastim biosimilar. This study assessed the efficacy and safety of FSK0808 in patients with breast cancer. One hundred and four breast cancer patients undergoing chemotherapy were enrolled in the study. FSK0808 was used to treat the neutropenia experienced by the patients in the course of their chemotherapy. Efficacy was evaluated by the recovery of absolute neutrophil count following FSK0808 administration based on the duration of neutropenia in patients who received pre- or postoperative chemotherapy containing fluorouracil, epirubicin and cyclophosphamide. Adverse events were evaluated in accordance with the Common Terminology Criteria for Adverse Events version 3.0. The incidence of febrile neutropenia and generation of an anti-granulocyte colony-stimulating factor antibody were also evaluated. The average duration of neutropenia in Cycle 2 was 2.2 days with a standard deviation of 1.5 days. The upper limit of the 97.5% one-sided confidence interval was 2.5 days and was confirmed not to exceed 3.0 days, which was defined as the threshold value of absolute neutrophil count recovery. The incidence of febrile neutropenia across all treatment cycles was 34.6%. Observed adverse drug reactions with an incidence of >5% were back pain (60.6%), bone pain (9.6%), alanine aminotransferase increase (8.7%), aspartate aminotransferase increase (5.8%) and arthralgia (5.8%). Production of the anti-granulocyte colony-stimulating factor antibody was not observed in any patient during the study. FSK0808 was safe and well tolerated in breast cancer patients undergoing chemotherapy and effectively stimulated neutrophil recovery.
- Open Access
- 16 April 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 36
Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer
Maspin is a unique member of the serine protease inhibitor superfamily and its expression is found in myoepithelial cells of normal mammary glands; therefore, it has been considered to be a myoepithelial marker. We previously reported that maspin was frequently expressed in biologically aggressive breast cancers. In turn, triple-negative (TN) breast cancer is a subtype of tumor with aggressive clinical behavior and shows frequent expression of basal markers. We hypothesized that maspin expression may be frequent and correlate with basal rather than myoepithelial markers in TN breast cancer.
- 16 April 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 36
Open AccessMaspin expression is frequent and correlates with basal markers in triple-negative breast cancer
Maspin is a unique member of the serine protease inhibitor superfamily and its expression is found in myoepithelial cells of normal mammary glands; therefore, it has been considered to be a myoepithelial marker. We previously reported that maspin was frequently expressed in biologically aggressive breast cancers. In turn, triple-negative (TN) breast cancer is a subtype of tumor with aggressive clinical behavior and shows frequent expression of basal markers. We hypothesized that maspin expression may be frequent and correlate with basal rather than myoepithelial markers in TN breast cancer.